Pharma M&A Feeding Frenzy Set To Continue As Investors Ask 'Who's Next?'
This article was originally published in Scrip
Executive Summary
A decade-long M&A cycle has hit a high point with Pfizer Inc.'s plan to devour Allergan PLC and the consolidation trend looks set to continue amid bullish investor sentiment, with most activity likely to be in the area of mid-sized branded drug makers, analysts say.